Phase II Study of Neoadjuvant Chemotheraphy (Gemcitabine and Nab-Paclitaxel vs. mFOLFIRINOX) and Sterotatic Body Radiation Therapy for Borderline Resectable Pancreatic Cancer
Phase of Trial: Phase II
Latest Information Update: 08 Dec 2014
At a glance
- Drugs Gemcitabine (Primary) ; Paclitaxel (Primary) ; Fluorouracil; Irinotecan; Oxaliplatin
- Indications Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 03 Dec 2014 Planned End Date changed from 1 Sep 2019 to 1 Dec 2019 as reported by ClinicalTrials.gov.
- 03 Dec 2014 Planned primary completion date changed from 1 Sep 2018 to 1 Dec 2018 as reported by ClinicalTrials.gov.